Krishna P L Bhat
Overview
Explore the profile of Krishna P L Bhat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim S, Joshi K, Ezhilarasan R, Myers T, Siu J, Gu C, et al.
Stem Cell Reports
. 2024 Oct;
19(10):1516.
PMID: 39389676
No abstract available.
2.
Cheng J, Li M, Motta E, Barci D, Song W, Zhou D, et al.
Cell Rep Med
. 2024 Jul;
5(8):101658.
PMID: 39053460
The DNA damage response (DDR) and the blood-tumor barrier (BTB) restrict chemotherapeutic success for primary brain tumors like glioblastomas (GBMs). Coherently, GBMs almost invariably relapse with fatal outcomes. Here, we...
3.
Chandra V, Li L, Le Roux O, Zhang Y, Howell R, Rupani D, et al.
Cancer Cell
. 2023 Dec;
42(1):85-100.e6.
PMID: 38157865
Microbes influence cancer initiation, progression and therapy responsiveness. IL-17 signaling contributes to gut barrier immunity by regulating microbes but also drives tumor growth. A knowledge gap remains regarding the influence...
4.
Modrek A, Eskilsson E, Ezhilarasan R, Wang Q, Goodman L, Ding Y, et al.
Front Oncol
. 2022 Sep;
12:941657.
PMID: 36059614
Treatment-resistant glioma stem cells are thought to propagate and drive growth of malignant gliomas, but their markers and our ability to target them specifically are not well understood. We demonstrate...
5.
Mercau M, Patwa S, Bhat K, Ghosh S, Rothlin C
Semin Immunopathol
. 2022 May;
44(5):725-738.
PMID: 35508671
Cell death, be it of neurons or glial cells, marks the development of the nervous system. Albeit relatively less so than in tissues such as the gut, cell death is...
6.
Valdebenito S, Audia A, Bhat K, Okafo G, Eugenin E
iScience
. 2020 Sep;
23(9):101450.
PMID: 32882515
Glioblastoma (GBM) is the most prevalent and aggressive tumor in the central nervous system. Surgical resection followed by concurrent radiotherapy (ionizing radiation [IR]) and temozolomide (TMZ) is the standard of...
7.
Day B, Lathia J, Bruce Z, DSouza R, Baumgartner U, Ensbey K, et al.
Acta Neuropathol
. 2019 Aug;
138(6):1033-1052.
PMID: 31463571
Glioblastomas (GBMs) are malignant central nervous system (CNS) neoplasms with a very poor prognosis. They display cellular hierarchies containing self-renewing tumourigenic glioma stem cells (GSCs) in a complex heterogeneous microenvironment....
8.
Conroy S, Kruyt F, Wagemakers M, Bhat K, den Dunnen W
Oncotarget
. 2018 Apr;
9(21):15721-15731.
PMID: 29644004
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by a high rate of vascularization. However, therapeutic targeting of the vasculature through anti-vascular endothelial growth factor (VEGF) treatment has been...
9.
Li M, Xiao A, Floyd D, Olmez I, Lee J, Godlewski J, et al.
Oncotarget
. 2017 Sep;
8(33):55319-55331.
PMID: 28903422
Glioblastoma (GBM) is the most common and lethal brain tumor. Gene expression profiling has classified GBM into distinct subtypes, including proneural, mesenchymal, and classical, and identifying therapeutic vulnerabilities of these...
10.
Audia A, Conroy S, Glass R, Bhat K
Front Oncol
. 2017 Jul;
7:143.
PMID: 28740831
Glioblastoma is the most common and highly malignant primary brain tumor, and patients affected with this disease exhibit a uniformly dismal prognosis. Glioma stem-like cells (GSCs) are a subset of...